Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Multiple Myeloma Clinical Trials

Protocol Number Title
1999LS060
MT1999-14 Unrelated or partially matched allogeneic donor stem cells for lymphoma, myeloma, and chronic lymphocytic leukemia
2004LS001
MT2003-13C : Autologous Transplantation for Multiple Myeloma
2005LS036
MT2005-02 Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Non-Myeloablative Preparative Regimen
2005LS043
MT2005-10 Transplantation of Unrelated Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloblative Preparative Regimen
2010NTLS145
MT2007-05R Late Effects in Survivors of Cancer, Stem Cell Transplantation or Blood Disorders From Digital Upgrade to Digital Revolution: A New Era in Survivor Research
2012OC065
MT2012-11C: Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
2013NTLS001
Feasibility of an active music making protocol with BMT patients and their parents.
2013OC003
MT2013-06C : Treatment of graft Failure after HSCT
2013OC013
MT2013-09C : Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases
2014CG126
MT2014-33R: Continued Long-Term Follow-up and Lenalidomide Maintenance Therapy for Patients Who have Enrolled on CTN 0702 (CTN 07LT)
2014LS020
MT2014-12:Phase I/II Study of Human Chorionic Gonadotropin and Epidermal Growth Factor Supplementation (Pregnyl?) to Support Tolerance and Repair As Adjunct Therapy in High-Risk or Refractory Acute Graft-Versus-Host Disease
2014NTLS071
Family-based studies of susceptibility to early onset disease
2015CG039
MT2015-11 : Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma (CTN1302)
2015CG185
MT2016-04 :Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination of Dendritic Cell/Myeloma Fusions (CTN 1401)
2015LS149
MT2015-17C :Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen
2015LS152
MT2015-32C : Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases
2015NTIS093
MT2015-21R: A follow-up study that evaluates the safety and clinical outcomes of subjects who have undergone hematopoietic stem cell transplantation with HSC835 (expanded umbilical cord blood hematopoietic stem cells)
2015NTLS018
MT2015-08R: Microbial, Graft and Host Interactions in Hematopoietic Cell Transplantation Reducing sepsis-related mortality in cancer patients through microbiome therapy
2016CG095
MT2016-13 :A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease (CTN 1501)
2016IS041
HM2016-16 : Multicenter Expanded Access Protocol of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients with EBV-Associated Viremia or Malignancies for Whom There are No Appropriate Alternative Therapies
2016IS064
MT2016-10: A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects with Chronic Graft Versus Host Disease
2016IS101
MT2016-31 A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
2016IS140
MT2016-36 A Phase I, Multicenter, Open-label, safety of Human Cord Blood Derived, Culture-Expanded, Natural Killer Cell (PNK-007) Infusion with subcutaneous Recombinant Human IL-2 (RHIL-2) following autologous stem cell transplant for Multiple Myeloma
2017NTLS052
HM2017-21 The Role of Gut Microbiota in Intestinal Barrier Damage in Acute Leukemia Patients Undergoing Inpatient Induction Chemotherapy

24 trials displayed